Differences in avidity of anti-post-translationally modified protein antibodies in mouse models and rheumatoid arthritis patients: not one-size-fits-all

• Published in: Rheumatic & musculoskeletal diseases open Vol. 10; no. 2; p. e004131
• Main Authors: van der Meulen, Stef, Zhang, Lu, van Veenendaal, Jacqueline M F, van der Woude, Diane, Trouw, Leendert A
• Format: Journal Article
• Language: English
• Published: England EULAR 24.05.2024; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Letter
• Subjects: Age; Animal Models; Animals; Anti-Citrullinated Protein Antibodies; Antibodies; Antibody Affinity; Antigens; Arthritis, Rheumatoid; Arthritis, Rheumatoid - immunology; Autoantibodies; Autoantibodies - immunology; Disease Models, Animal; Humans; Mice; Patients; Protein Processing, Post-Translational; Proteins; R&D; Research & development; Rheumatoid arthritis; Rheumatology; Tetanus; Anti-Citrullinated Protein Antibodies; Arthritis, Rheumatoid; Autoantibodies
• ISSN: 2056-5933; 2056-5933
• DOI: 10.1136/rmdopen-2024-004131

Following immunisation with MSA containing the different PTMs, we could readily detect (auto)antibodies in mice immunised with OVA, MSA-CarP, MSA-AGE, MSA-AL and MSA-MAA, as shown in figure 1A. The avidity of the anti-Cit response observed in this small number of patients corresponds to the study of Yamada et al3 and our earlier work.4 This research highlights that within the anti-PTM autoantibodies not only ACPA is of low avidity but also anti-CarP, anti-AL and anti-AGE. DvdW has received research grants from Inova diagnostics, FOREUM (Foundation for Research in Rheumatology) and ZonMw (the Netherlands Organization for Health Research and Development), as well as consulting fees from Galapagos.